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Platinum nanoparticles (NP-Pt) are noble metal nanoparticles with unique physiochemical properties that have
recently elicited much interest in medical research. However, we still know little about their toxicity and influence
on general health. We investigated effects of NP-Pt on the growth and development of the chicken embryo model
with emphasis on brain tissue micro- and ultrastructure. The embryos were administered solutions of NP-Pt injected
in ovo at concentrations from 1 to 20 μg/ml. The results demonstrate that NP-Pt did not affect the growth and
development of the embryos; however, they induced apoptosis and decreased the number of proliferating cells in
the brain tissue. These preliminary results indicate that properties of NP-Pt might be utilized in brain cancer therapy,
but potential toxic side effects must be elucidated in extensive follow-up research.
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Platinum (Pt) is a noble metal with unique physiological
and chemical properties widely used in chemistry, phy-
sics, biology, and medicine. Regarding the biological
activities of Pt, it is known that Pt compounds have the
ability to arrest the cell cycle [1,2] and cause DNA
strand breaks. The DNA damage is caused by Pt ions,
which attach to N7 sites of DNA guanine bases and,
after hydrolysis of Pt-Cl bonds, form adducts with the
DNA double helix [2,3]. These properties of Pt are
exploited in cancer therapy in the form of antineoplastic
drugs to treat different types of cancer such as head,
neck, brain [4], testicular, bladder, ovarian, or uterine
cervix carcinomas [5]. However, toxic side effects of
Pt-based drugs are major drawbacks in cancer therapy
[6,7].
Nanotechnology has introduced possibilities for using
alternate forms of elements - nanoparticles. Nanoparticles
have unique physiochemical features because of their
small size (<100 nm), large surface-to-mass ratio, excep-
tional quantum characteristics [8], and consequently
unique biological properties. Smaller nanoparticles can* Correspondence: ach@sund.ku.dk
3Department of Veterinary Clinical and Animal Sciences, University of
Copenhagen, Groennegaardsvej 3, Frederiksberg 1870, Denmark
Full list of author information is available at the end of the article
© 2013 Prasek et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pmove across cellular and also nuclear membranes and are
able to penetrate cells and intracellular structures, and
target defined points within the body [9,10]. Platinum
nanoparticles (NP-Pt) have recently elicited much interest
because of their physicochemical properties such as cata-
lytic activity and high reactivity [11]. NP-Pt, as metal
structures (Pt0), differ significantly from platinum salts
and have quite different chemical properties when admin-
istered to an organism. They are a very limited source of
ions, and consequently, the process of forming platinum
salts is very slow and restricted. However, the solubility
and, consequently, the bioavailability of NP-Pt depend on
their size [12]. Although it has been demonstrated that
small doses of NP-Pt have negligible toxic effects on
chicken and zebra fish embryos [13], they might impinge
the cell structures [12].
It has been demonstrated that hadron cancer therapy
can be amplified by simultaneous application of NP-Pt,
resulting in the production of hydroxyl radicals causing
lethal DNA damage by double-strand breaks [14]. Fur-
thermore, DNA damage could also be induced by the
attack of OH groups linked with NP-Pt on DNA phos-
phate groups [2]. NP-Pt can also cause cell cycle arrest
and induction of apoptosis through the release of Pt2+
ions from the nanoparticles as a result of H2O2 gene-
ration due to the low pH in endosomes [1]. It was alson Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Prasek et al. Nanoscale Research Letters 2013, 8:251 Page 2 of 9
http://www.nanoscalereslett.com/content/8/1/251demonstrated that DNA double-strand breaks are
caused by Pt2+ ions formed during the incubation of
NP-Pt with cancer cells [15]. However, the consequences
of introducing NP-Pt into an organism are still not well
documented, especially when even very small amounts
of nanoparticles or released ions may overcome the
blood–brain barrier (BBB), enter the brain tissue, and
affect the BBB and brain function. It has also been
reported that various types of nanoparticles, in different
sizes from 20 to 300 nm and produced from different
materials, may cause cell death by apoptosis in the brain
tissue [16].
In the present study, we hypothesized that NP-Pt may
affect the growth and development of embryos and, fur-
thermore, can cross the BBB and penetrate the brain tis-
sue, affecting brain morphology. Consequently, the
objective of this preliminary work was to investigate the
effects of NP-Pt on embryo growth and development
with an emphasis on brain morphology, concerning their
potential applicability in brain cancer therapy.
Methods
Nanoparticles
Hydrocolloids of NP-Pt were obtained from Nano-Tech
Polska (Warsaw, Poland). They were produced by a pat-
ented electric nonexplosive method [17] from high pur-
ity metal (99.9999%) and high purity demineralized
water. The shape and size of the nanoparticles were
inspected by transmission electron microscopy (TEM)
using a JEOL JEM-1220 TE microscope at 80 KeV (JEOL
Ltd., Tokyo, Japan), with a Morada 11 megapixel camera
(Olympus Corporation, Tokyo, Japan) (Figure 1). The di-
ameters of the Pt particles ranged from 2 to 19 nm. A
sample of Pt for TEM was prepared by placing droplets
of the hydrocolloids onto Formvar-coated copper grids
(Agar Scientific Ltd., Stansted, UK). Immediately after
drying the droplets in dry air, the grids were insertedFigure 1 TEM image of platinum nanoparticles. Bar scale
100 nm.into the TE microscope (Figure 1). The zeta potential of
the nanoparticle hydrocolloids was measured by electro-
phoretic light-scattering method, using a Zetasizer
Nano-ZS90 (Malvern, Worcestershire, UK). Each sample
was measured after 120 s of stabilization at 25°C in
20 replicates. The mean zeta potential of the Pt
nanoparticles was −9.6 mV.
Embryo model
Based on Polish law Article 2 of the act dated 21 January
2005 concerning the experiments on animals (journal of
law is dated 24 February 2005), there is no need to sub-
mit an application to the local ethics committee for issu-
ing an opinion about studies where the chicken embryo
is used. According to this act, chicken embryo is not def-
inite as the animal. Fertilized eggs (n = 150; 56 ± 2.2 g)
from hens of the Ross line were obtained from a com-
mercial hatchery and stored at 12°C for 4 days. After 4
days, the eggs were weighed and randomly divided into
six groups (n = 25 eggs per group). The control group
was not treated, while the other groups were treated
with 1, 5, 10, 15, or 20 μg/ml of NP-Pt solutions. The
experimental solutions were given in ovo by injection
into the albumen (at two-thirds of the egg's height from
the blunt end) using a sterile 1-ml insulin syringe. Injec-
tion consisted of 0.3-ml NP-Pt hydrocolloid. The injec-
tion holes were sterilized, and the eggs were then
incubated at 37.5°C and 60% humidity and were turned
once per hour for 19 days.
At day 20 of incubation, the embryos were sacrificed
by decapitation. Embryos and organs (brain, heart, liver,
spleen, bursa of Fabricius) were weighed and evaluated
by Hamburger and Hamilton [18] (HH) standards.
Biochemical indices
Blood serum samples were collected from the jugular
vein on the 20th day of incubation. The samples were
centrifuged at 3,000 rpm for 15 min (Sorvall ST 16,
Thermo Fisher Scientific, Waltham, MA, USA), and
concentrations of alanine aminotransferase (ALT), as-
paragine aminotransferase, lactate dehydrogenase, alka-
line phosphatase (ALP), glucose level, and blood urea
nitrogen were measured in the blood serum. Biochemis-
try markers were examined using a dry chemistry equip-
ment Vitros DT 60 II (Johnston and Johnston, New
Brunswick, NJ, USA).
Brain morphology: examination of brain tissue
microstructure
Chicken brains (n = 12), three from the control group
and nine from groups treated with 1, 10, and 20 μg/ml
of NP-Pt solutions, were sampled and fixed in 10% buff-
ered formalin (pH 7.2). Fixed samples were dehydrated
in a graded series of ethanols, embedded in Paraplast,
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RM 2265, Leica, Nussloch, Germany). The morphology
of the chicken brains was examined using hematoxylin-
eosin staining. Proliferating cells were identified via
immunohistochemistry using antibodies directed against
proliferating cell nuclear antigen (PCNA) [19]. Apo-
ptotic cells were detected using rabbit polyclonal anti-
caspase-3 antibody (C8487, Sigma-Aldrich Corporation,
St. Louis, MO, USA). Sections for this purpose were in-
cubated for 1 h with the rabbit polyclonal anti-caspase-3
antibody at room temperature and were visualized with
Dako EnVision+System-HRP (Dako K 4010, Dako A/S,
Glostrup, Denmark), while further procedures were
identical as for PCNA detection. The proliferation and
apoptosis levels were expressed as the number of
PCNA-positive cells and caspase-3-positive cells in the
chicken brain cortex, respectively (the area counted was
3,500 μm2).
Morphological observations and morphometric mea-
surements (number of PCNA-positive cells, caspase-
3-positive cells) were done using a Nikon ECLIPSE 90i
microscope (at ×400 magnification) connected to a
digital camera, Nikon DS5-U1, and a computer image
analysis system, NIS-Elements AR (Nikon Corporation,
Tokyo, Japan).
Examination of brain tissue ultrastructure
Brain tissue morphology was examined by TEM. The
tissues were fixed for TEM in fixative consisting of 1%
glutaraldehyde in PBS at pH 7.2. After fixation, the tis-
sues were post-fixed in 1% osmium tetroxide and
dehydrated in a graded series of ethanols. The tissues
were embedded in a mixture of Araldite and Epon.
Ultrathin sections (100 nm) were cut on an ultramicro-
tome (EM UC6, Leica). The samples were viewed using
a JEM-1220 TE microscope at 80 KeV (JEOL Ltd.), with
a Morada 11 megapixel camera (Olympus Corporation).
Statistical analysis
Data analysis was carried out by monofactorial analysis
of variance, and the differences between groups were
tested by multiple range Duncan test using Statistica ver-
sion 10.0 (StatSoft, Tulsa, OK, USA). Differences with




Embryo visualization did not show any genetic defects
among the groups. Furthermore, comparison with HH
standards showed that all embryos had developed
normally. Survival, body weight, and weight of the brain,
heart, spleen, and bursa of Fabricius were not sig-
nificantly different between all the groups (Table 1).However, the weight of the liver was significantly dif-
ferent in some NP-Pt groups compared to the control
group. None of the biochemical indices measured in the
blood sera of the embryos showed significant effects of
the treatments (Table 2).
Brain morphology: examination of brain tissue
microstructure
Cell numbers in the brain cortex (area counted 3,500
μm2) were not significantly different between the groups
(Table 3). However, histological evaluation of brain
morphology revealed pathological changes in the brain
structure in embryos treated with NP-Pt, showing a
moderate degradation of the cerebellar molecular layer,
neuronal loss in the cerebellum cortex, and astrocytosis
(Figure 2).
Examination of brain tissue ultrastructure
TEM examination of brain tissue morphology showed
no abnormalities in the control group. However, in em-
bryos treated with NP-Pt, degradation of the mitochon-
dria, rounded nuclei with dispersed chromatin, and
vacuoles in the cytoplasm were seen (Figure 3).
Immunohistochemical measurements showed that the
number of PCNA-positive nuclei significantly decreased
after in ovo injection of NP-Pt solutions, attaining the
lowest value in the 20-μg/ml group (Figure 4).
Immunodetection of PCNA-positive nuclei by immuno-
histochemical methods was carried out in cross sections
of the granular layer of the cerebellar cortex. PCNA-
positive nuclei were brown, and PCNA-negative nuclei
were blue (Figure 5). Immunohistochemical measure-
ments showed the numbers of caspase-3-positive cells
significantly increased in the NP-Pt groups compared to
those in the control group (Figure 4). The greatest
increase was observed in the group receiving 20 μg/ml
of NP-Pt. Cross sections of the granular layer of cerebral
cortex were also immunostained with the caspase-3 anti-
body. Caspase-3-positive cells showed brown cytoplasm,
while the cytoplasm of caspase-3-negative cells was blue
(Figure 6).
Discussion
In the present work, we studied the effects of different
concentrations of platinum nanoparticle hydrocolloids
administered to chicken embryos on their growth and
development as well as on the morphological and mo-
lecular status of the brain at the end of embryogenesis.
The chicken embryo is a very useful experimental
model, developing without influence of the maternal or-
ganism and allowing very fast and precise assessments of
toxicity [21,22]. Moreover, NP-Pt were administered at
the beginning of embryogenesis, when, consequently,
nanoparticles could potentially penetrate the entire
Table 1 Survival, body weight, and selected organ weight in control and groups treated with different NP-Pt
concentrations
Control 1.0 μg/ml 5.0 μg/ml 10.0 μg/ml 15.0 μg/ml 20.0 μg/ml SEM P value
Survival 25 20 19 20 21 21 0.4837 0.1152
Body 50.77 53.97 52.97 53.15 54.30 52.00 5.043 0.2510
Brain 0.434 0.453 0.328 0.474 0.471 0.455 0.0564 0.6855
Heart 0.165 0.146 0.152 0.154 0.145 0.128 0.0475 0.0806
Liver 0.559 b 0.434 a 0.475 a 0.52 ab 0.495 a 0.516 ab 0.1645 0.0405*
Spleen 0.013 0.010 0.015 0.012 0.010 0.009 0.0122 0.5891
Bursa of Fabricius 0.030 0.025 0.028 0.029 0.028 0.030 0.2559 0.9815
Chicken embryo survival (number of embryos), body weight (g), and weight of selected organs (g/100 g body weight) in the control group and in groups treated
with different concentrations of platinum nanoparticles (1 to 20 μg/ml). SEM standard error of the mean. Means with different letters differ significantly; *P < 0.05.
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cells, and brain structures, both before and after the ap-
pearance of the BBB [7].
Our studies demonstrated that NP-Pt injected into
eggs at concentrations of 1, 5, 10, 15, and 20 μg/ml did
not influence the growth and development of the
chicken embryos. Their survival as well as examination
of their morphology according to HH standards of
chicken embryo development did not differ between the
control and NP-Pt groups. No overt abnormalities that
could indicate mutagenic effects of NP-Pt were ob-
served. These results are in agreement with a recent in-
vestigation demonstrating no toxic effects of NP-Pt on
the growth and development of Danio rerio embryo
[13]. Furthermore, they are in agreement with our own
previous studies regarding the effects of nanoparticles of
silver, silver/palladium alloy, and gold, showing no harm-
ful effects on growth and development of embryos when
the nanoparticles were used at concentrations below 100
μg/ml [23-27]. In contrast to NP-Pt, platinum-based
drugs such as cis-dichlorodiammineplatinum (II) (cis-
platin) do show toxic effects on the development and
mortality of rat embryos [28]. Platinum compounds also
have toxic effects on mouse embryo development during
organogenesis and histogenesis [29].
In our experiment, body weight and the weights of se-
lected organs in the chicken embryos were not signifi-
cantly affected by NP-Pt injection; however, liver weight
was generally lower in the NP-Pt groups compared toTable 2 Activities of biochemical indices in the control and in
Biochemical indices Reference valuesa Control
Asparagine aminotransferase (U/l) 90 to 226 193.1
Alanine aminotransferase (U/l) 9 to 14 11.78
Lactate dehydrogenase (U/l) 1,100 to 5,275 1,135
Alkaline phosphatase (U/l) 3,780 to 14,800 6,300
Blood urea nitrogen (mg/Dl) 7.0 to 17.1 5.7
Glucose level (mg/Dl) 110 to 306 219
SEM standard error of the mean. aReference values of biochemical indices for poultthe control group, which might indicate some harmful
effects of NP-Pt. Subsequently, we measured the activ-
ities of hepatic enzymes in blood serum (ALT, AST, and
ALP) as markers of the functional and morphological
state of the liver [5], but these indices were not affected
by NP-Pt. Consequently, our preliminary observations
regarding growth and development suggest that NP-Pt
do not seem to be harmful when evaluated at the whole
body and organ level; however, potential subclinical
changes might occur at the tissue and molecular levels.
The chicken embryo is a suitable model to study
neurotoxicity because the BBB is fully developed and
functioning after 15 days of incubation [7]. The key role
of the BBB is protecting the brain from toxic substances.
On the other hand, the blocking role of the BBB is prob-
lematic because drugs used to treat many diseases of the
central nervous system are unable to cross this highly
specific barrier [30]. Application of NP-Pt at the begin-
ning of embryogenesis makes it possible for NP-Pt to
penetrate different tissues, including brain precursor
cells and structures. Moreover, enclosed and separated
from the mother and environment, the organism has no
possibilities to remove the nanoparticles from the egg,
and consequently, the embryos were permanently ex-
posed to PN-Pt during 20 days of embryogenesis (before
and after BBB occurrence).
The present results demonstrated that PN-Pt did not
cause any difference in brain weight evaluated at the end
of embryogenesis. Histological assessment of the braingroups treated with different NP-Pt concentrations
1.0 μg/ml 10.0 μg/ml 20.0 μg/ml SEM P value
214.2 183.4 170.1 15.35 0.4845
8.53 17.00 18.25 4.399 0.2182
1,121 778 1,026 83.6 0.2073
4,800 4,030 7,033 47.8 0.0712
8.0 7.5 8.0 0.41 0.1272
213 169 203 8.2 0.1269
ry [20].
Table 3 Numbers of cells in the brain cortex in the control and in groups treated with different NP-Pt concentrations
Control 1.0 μg/ml 10.0 μg/ml 20.0 μg/ml SEM P value
Number of cells 613 583 600 697 6.5 0.448
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the number of brain cortex cells was not affected. How-
ever, more detailed examination of the brain tissue ultra-
structure indicated some neurotoxic symptoms from
NP-Pt treatment, including deformation and degradation
of the mitochondria. Similar results were obtained for
cisplatin, showing mitochondrial and nuclear DNA dam-
age in the dorsal root ganglia [31]. Thus, not only plat-
inum salts but also NP-Pt, via mitochondrial disruption,
may lead to mitochondria-dependent apoptosis. Al-
though almost half the neuronal cells die by apoptosis
during normal brain development, this physiological
process may be enhanced under toxic conditions [32].
However, the stimulation of mechanism of apoptosis
within tumor cells is considered a highly advanced can-
cer therapy [33] and, in this respect, NP-Pt can enhance
the apoptosis of cancer cells.
Cytochrome c released from the mitochondria into the
cytosol is one of the first steps in the mitochondrial
apoptotic pathway. Cytochrome c and ATP are bound to
the apoptotic protease-activating factor-1 [34]. The mer-
ger of these two structures creates an apoptosome and
activates caspase-9. Active caspase-9 is responsible forFigure 2 Cross sections through the granular layer of the cerebral co
(C) 10 μg/ml, (D) 20 μg/ml. Black arrows, astrocytosis; white arrows, neuronthe activation of the executioners, caspase-3 and
caspase-7 [32,35]. We examined the activity of caspase-3
to detect apoptosis. Our results showed an increasing
level of caspase-3-positive cells in chicken brain samples
from groups treated with NP-Pt. These results agree
with studies suggesting that platinum-based drugs trig-
ger DNA damage, which induces apoptosis with the acti-
vation of caspase-3 [36,37].
Opposing apoptosis is the process of cell proliferation,
and thus, the interaction between apoptosis and prolifer-
ation, observed after platinum-based drug treatment, is a
key factor in cancer therapy [38]. To examine the status
of proliferation after NP-Pt treatment, we also identified
the level of PCNA-positive nuclei in the brain tissue.
The immunohistochemical analyses showed a decline in
PCNA-positive nuclei in the NP-Pt groups. PCNA is a
key factor in the replication of genetic material and is in-
volved in the cell cycle and proliferation processes [39].
This may indicate that NP-Pt analogs to platinum-based
drugs, where Pt exists in cationic form, activate apop-
tosis and at the same time suppress proliferation. How-
ever, the toxic side effects of NP-Pt seem to be much
smaller than those caused by platinum-based drugsrtex stained with hematoxylin and eosin. (A) Control, (B) 1 μg/ml,
al loss. Scale bars 10 μm.
Figure 3 TEM images of brain tissue after treatment with platinum nanoparticles. Concentration of NP-Pt was at 20 ppm. Arrows signify
(A) vacuoles, (B) degradation of endoplasmic reticulum, and (C, D) degradation of the mitochondria. Scale bars 500 nm.
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be used in cancer therapy instead of ionic Pt, especially
for brain cancer, because the particles can pass the BBB
and reach the tumor tissue in the brain.
Conclusions
Platinum nanoparticles administered to chicken embryos
at the beginning of embryogenesis at concentrations of 1Figure 4 Numbers of caspase-3-positive cells and PCNA positive nucl
the mean. Bars with different superscripts differ significantly (P < 0.05).to 20 μg/ml did not affect the growth and development
of the embryos. Examination of neurotoxicity after NP-
Pt treatment showed no changes in the number of cells
in the brain cortex; however, analyses of brain tissue
ultrastructure revealed mitochondria degradation. NP-Pt
activated apoptosis as well as decreased the rate of pro-
liferation of the brain cells. These preliminary results in-
dicate that properties of NP-Pt might be utilized forei (counting area = 3,500 μm2). Error bars indicate standard error of
Figure 5 Cross sections of a granular layer in the cerebral cortex by PCNA staining. (A) Control, (B) 1 ppm, (C) 10 ppm, and (D) 20 ppm.
PCNA-positive nuclei (arrows). Scale bars 10 μm.
Figure 6 Cross sections of a granular layer in the cerebral cortex by anti-caspase-3 staining. (A) Control, (B) 1 μg/ml, (C) 10 μg/ml,
(D) 20 μg/ml. Anti-caspase-3-positive cells (arrows). Scale bars 10 μm.
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must be elucidated in extensive follow-up research.
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